We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Supplementation With Goldenseal (Hydrastis canadensis), but not Kava Kava (Piper methysticum), Inhibits Human CYP3A Activity In Vivo.
- Authors
Gurley, B. J.; Swain, A.; Hubbard, M. A.; Hartsfield, F.; Thaden, J.; Williams, D. K.; Gentry, W. B.; Tong, Y.
- Abstract
The effects of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on human CYP3A activity were evaluated using midazolam (MDZ) as a phenotypic probe. Sixteen healthy volunteers were randomly assigned to receive either goldenseal or kava kava for 14 days. Each supplementation phase was followed by a 30-day washout period. MDZ (8 mg, per os) was administered before and after each phase, and pharmacokinetic parameters were determined using standard non-compartmental methods. Comparisons of pre- and post-supplementation MDZ pharmacokinetic parameters revealed significant inhibition of CYP3A by goldenseal (AUC(0–∞), 107.9±43.3 vs 175.3±74.8 ng·h/ml; Cl/F/kg, 1.26±0.59 vs 0.81±0.45 l/h/kg; T1/2, 2.01±0.42 vs 3.15±1.12 h; Cmax, 50.6±26.9 vs 71.2±50.5 ng/ml). MDZ disposition was not affected by kava kava supplementation. These findings suggest that significant herb–drug interactions may result from the concomitant ingestion of goldenseal and CYP3A substrates.Clinical Pharmacology & Therapeutics (2008) 83, 61–69; doi:10.1038/sj.clpt.6100222; published online 9 May 2007
- Subjects
GOLDENSEAL; DRUG interactions; DRUG side effects; CLINICAL medicine; HYDRASTIS
- Publication
Clinical Pharmacology & Therapeutics, 2008, Vol 83, Issue 1, p61
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1038/sj.clpt.6100222